Tech Company Financing Transactions
Ochre Bio Funding Round
Ochre Bio closed a $9.6 million Seed funding round on 6/17/2021. Backers included Khosla Ventures, Apollo Ventures and Backed VC.
Transaction Overview
Company Name
Announced On
6/17/2021
Transaction Type
Venture Equity
Amount
$9,600,000
Round
Seed
Investors
Khosla Ventures (Lead Investor) (Alex Morgan)
Proceeds Purpose
The funding will be used to advance the development of Ochre Bio's RNA therapies and expand their deep phenotyping platform to identify and validate new liver targets.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
2093 Philadelphia Pike
Claymont, DE 19703
USA
Claymont, DE 19703
USA
Phone
Undisclosed
Website
Email Address
Overview
Ochre Bio is a biotechnology company developing RNA medicines for chronic liver diseases, a top ten global killer. We uncover new biological pathways by using advances in 'deep phenotyping', and then study our medicines in human livers kept alive on machines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jack O' Meara
Chief Scientific Officer
Quin Wills
VP - Finance
Paul Foster
Browse more venture capital transactions:
Prev: 6/17/2021: Vianai venture capital transaction
Next: 6/17/2021: Gloat venture capital transaction
Share this article
News on VC Transactions
We do our best to report on tech company VC transactions. VC investment data records reported here are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs